Abstract
Potent antiresorptive agents have been developed for the treatment of osteoporosis and bone disorders. There are few agents available that stimulate bone formation. Recently, treatment with parathyroid hormone was found to induce a potent increase in hip and lumbar bone mineral density (BMD). The present review focus on growth hormone (GH) / growth hormone secretagogues (GHSs). GH / GHSs stimulates bone turnover, thereby increasing bone mass and density.
Keywords: Growth hormone, secretagogue, bone mineral content, bone mineral density
Current Pharmaceutical Design
Title: The Importance of Growth Hormone (GH) and GH Secretagogues for Bone Mass and Density
Volume: 8 Issue: 23
Author(s): Johan Svensson
Affiliation:
Keywords: Growth hormone, secretagogue, bone mineral content, bone mineral density
Abstract: Potent antiresorptive agents have been developed for the treatment of osteoporosis and bone disorders. There are few agents available that stimulate bone formation. Recently, treatment with parathyroid hormone was found to induce a potent increase in hip and lumbar bone mineral density (BMD). The present review focus on growth hormone (GH) / growth hormone secretagogues (GHSs). GH / GHSs stimulates bone turnover, thereby increasing bone mass and density.
Export Options
About this article
Cite this article as:
Svensson Johan, The Importance of Growth Hormone (GH) and GH Secretagogues for Bone Mass and Density, Current Pharmaceutical Design 2002; 8 (23) . https://dx.doi.org/10.2174/1381612023393413
DOI https://dx.doi.org/10.2174/1381612023393413 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists
Current Medicinal Chemistry Differential Characteristics of HMGB2 Versus HMGB1 and their Perspectives in Ovary and Prostate Cancer
Current Medicinal Chemistry Polymorphism of UDP-Glucuronosyltransferase and Drug Metabolism
Current Drug Metabolism Epigenetic Regulation of Epithelial-Mesenchymal Transition by Hypoxia in Cancer: Targets and Therapy
Current Pharmaceutical Design The Emerging Role of Melatonin Agonists in the Treatment of Major Depression: Focus on Agomelatine
CNS & Neurological Disorders - Drug Targets Activation of LINE-1 Retrotransposon Increases the Risk of Epithelial-Mesenchymal Transition and Metastasis in Epithelial Cancer
Current Molecular Medicine Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy Design and Development of Oxazol-5-Ones as Potential Partial PPAR-γ Agonist Against Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Biological Evaluation of Estradiol-Core Derivatives Bearing a Fused γ-Lactone as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1
Current Enzyme Inhibition Leveraging Cell Cycle Analysis in Anticancer Drug Discovery to Identify Novel Plasmodial Drug Targets
Infectious Disorders - Drug Targets Proteomics Approach to Illustrate Drug Action Mechanisms
Current Drug Discovery Technologies Molecular Basis of Therapeutic Strategies for Breast Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Precision Medicine Approach in Prostate Cancer
Current Pharmaceutical Design Potential Prognostic Predictors and Molecular Targets for Skin Melanoma Screened by Weighted Gene Co-expression Network Analysis
Current Gene Therapy The Metabolism of Anticancer Drugs by the Liver: Current Approaches to the Drug Development Process
Current Drug Metabolism Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
Current Drug Targets Current Methods and Research Progress in Nanomaterials Risk Assessment
Current Drug Metabolism The Role of microRNAs in the Pathogenesis and Treatment of Hematopoietic Malignancies
Current Pharmaceutical Design Trichostatin A - like Hydroxamate Histone Deacetylase Inhibitors as Therapeutic Agents: Toxicological Point of View
Current Medicinal Chemistry Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design